XQ-509

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameXQ-509
Drug Alias Namebivalent (-)-meptazinol derivative (Shanghai Center for Drug Discovery & Development)XQ-509
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitorsAcetylcholinesterase inhibitors
TargetsAcetylcholinesteraseBeta amyloid A4 protein
Therapy Area/IndicationsDementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Municipal Biological Pharmaceutical Science and Technology Industry Promotion Center
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Municipal Biological Pharmaceutical Science and Technology Industry Promotion Center
Inactive CompaniesN/A
Active IndicationsDementia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A